Observational studyBMC infectious diseases2017

The efficacy, safety, and feasibility of inhaled amikacin for the treatment of difficult-to-treat non-tuberculous mycobacterial lung diseases.

Kazuma Yagi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.